(ShareCast News) - Numis sell-side analysts provided a list of their top picks among large and small cap stocks across the market, including ARM Holdings, Virgin Money, Derwent London, Tullow Oil, Northgate and Vectura. After another strong set of quarterly results, ARM remains the top pick as Numis
Read more(ShareCast News) - Numis sell-side analysts provided a list of their top picks among large and small cap stocks across the market, including ARM Holdings, Virgin Money, Derwent London, Tullow Oil, Northgate and Vectura. After another strong set of quarterly results, ARM remains the top pick as Numis
Read more(ShareCast News) - Vectura - which focuses on the development of pharmaceutical therapies for airways diseases - has received a letter of intent from a Skyepharma shareholder supporting the companies' proposed merger. Vectura said River and Mercantile Asset Management, which owns just under 4.8m Sky
Read more* Agreed offer values SkyePharma at 410.15 pence a share * Combined group market value more than 1 billion pounds (Adds more on rationale for deal, comment from CEO) By Ben Hirschler LONDON, March 16 (Reuters) - Respiratory drug specialist Vectura has agreed to buy rival SkyeP
Read more(ShareCast News) - Vectura and Skyepharma have reached an agreement on the terms of a recommended merger. Under the terms of the deal, Skyepharma shareholders will get 2.7977 new Vectura shares for each Skyepharma share. Based on Vectura's closing price of 146.60p on Tuesday, this values Skyepharma
Read more(ShareCast News) - Virgin Money: Nomura starts coverage at buy with a target of 445p. Domino's Pizza: Credit Suisse upgrades to outperform with a target price of 1100p. BBA Aviation: Goldman Sachs downgrades to neutral with 181p target. Greencore: Societe Generale reiterates hold with a 386p targe
Read more(ShareCast News) - Vectura Group's inhaler and formulation technology received a boost on Wednesday, with the completion of a significant milestone on the development of the VR315 product. The FTSE 250 company confirmed that the clinical study report had been finalised, triggering a cash milestone p
Read more